MMP2 and relapsing-remitting multiple sclerosis: In this paper, we considered MMP-9 and MMP-2 plasma levels in RRMS patients treated with natalizumab, at different number of infusions, showing that MMP-2 plasma levels remained unchanged in all RRMS patients, independently from the exposition to natalizumab treatment.